Company Encyclopedia
View More
name
Unicycive Therapeutics
UNCY.US
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc.
1.930 T
UNCY.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Unicycive Therapeutics unveils new kidney disease treatment pipeline in latest corporate presentation

    Unicycive Therapeutics Inc. has unveiled its kidney disease treatment pipeline, focusing on oxylanthanum carbonate (OLC) for hyperphosphatemia in dialysis patients. The company plans to resubmit the NDA for OLC by year-end after resolving FDA compliance issues. OLC aims to reduce pill burden, addressing unmet needs. Unicycive is also developing UN-494 for acute and chronic kidney disease. The company has a cash runway until 2027 to support its clinical and commercial activities.

    Reuters·
    US
    UNCY
    -4.15%
    Reuters·
    US
    UNCY
    -4.15%

    After-Hours Spotlight: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, Protara Gain Post-Close

    Biotechnology and pharmaceutical companies, including Jasper Therapeutics, NRx Pharmaceuticals, and Unicycive Therapeutics, saw notable gains in after-hours trading. Jasper surged 21.51% after announcing a webinar on study findings. NRx climbed 13.39% with updates on investigational drugs. Unicycive rose 5.42% with upcoming event participation. Other companies like Spruce Biosciences, Evaxion, Solana, and Protara Therapeutics also experienced gains due to corporate updates and event announcements.

    rttnews·
    US
    NRXP
    -3.28%
    US
    JSPR
    -8.06%
    US
    UNCY
    -4.15%
    rttnews·
    US
    NRXP
    -3.28%
    US
    JSPR
    -8.06%
    US
    UNCY
    -4.15%

    Arcturus Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

    Arcturus Therapeutics Holdings Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference with a fireside chat on December 2, 2025, at 12:30 p.m. ET. This information was originally published by Arcturus Therapeutics via Business Wire.

    Reuters·
    US
    ARCT
    +4.39%
    Reuters·
    US
    ARCT
    +4.39%

    HC Wainwright Issues Negative Estimate for UNCY Earnings

    HC Wainwright has lowered its Q4 2025 earnings per share estimate for Unicycive Therapeutics to ($0.35) from $0.50, maintaining a "Buy" rating with a $22.00 price target. The stock has a "Moderate Buy" consensus with a $34.33 target. Unicycive's stock rose 6.4% to $5.67, with a market cap of $121.85 million. Institutional investors own 40.42% of the stock. The company develops therapies for kidney diseases, including Renazorb and UNI 494.

    Market Beat·
    US
    UNCY
    -4.15%
    Market Beat·
    US
    UNCY
    -4.15%

    Unicycive Therapeutics: Buy Rating Backed by Promising OLC Progress and Strategic Market Positioning

    Analyst Jason McCarthy from Maxim Group maintains a Buy rating on Unicycive Therapeutics with a $30 price target, citing progress in addressing FDA's response for OLC treatment and promising Phase 2 study results. The company plans to resubmit the NDA by year-end, potentially leading to a new PDUFA date in 2026. Strategic market positioning and innovative formulation support the Buy rating, with H.C. Wainwright also maintaining a Buy rating at a $22 price target.

    Tip Ranks·
    US
    UNCY
    -4.15%
    Tip Ranks·
    US
    UNCY
    -4.15%
    © 2025 Longbridge｜Disclaimer